Policy analysis reveals restrictive eligibility criteria reduce generalizability in oncology, suggesting broader initial enrollment improves clinical relevance.
Specific patient populations are often excluded from oncology trials without clear reasons, which renders results less clearly applicable to all patients. A more logical approach would be to study safety in a broad population and modify criteria as knowledge emerges.
No takes yet. Share an insight, caveat, or question.
Beaver et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: